Although vasodilator drugs acutely reduce regurgitation and improve cardiac performance in aortic insufficiency, their long-term effects on left ventricular size and function are uncertain. Consequently, we performed a double-blinded, placebo-controlled trial using hydralazine in 80 minimally symptomatic patients who had clinically stable, moderate-to-severe aortic insufficiency. Patients randomized to hydralazine displayed a progressive reduction in left ventricular end-diastolic volume index (LVEDVI) measured by radionuclide angiography, the predetermined end point of the study. At 24 months, mean LVEDVI had been reduced by 30 38 ml/m2, an 18% reduction from baseline. In contrast, LVEDVI changed minimally in patients randomized to placebo, and the intergroup differences over time were statistically significant (p<0.03). The hydralazine group also experienced reductions in left ventricular end-systolic volume index and increases in ejection fraction that were significantly different (both p<0.01) from changes in placebo-treated patients. These findings show that long-term treatment with hydralazine reduces the volume overload in aortic insufficiency and suggest that such therapy may have a beneficial effect on the natural history of the disease. (Circulation 1988;78:92-103) P revious studies have shown that vasodilator drugs acutely reduce the regurgitant volume and improve cardiac performance in aortic insufficiency. 1-7 Consequently, vasodilator therapy has emerged as an important modality for the shortterm management of patients with this lesion. These findings also raise the possibility that long-term therapy may chronically reduce the volume overload to the left ventricle.
Long-term Vasodilator Therapy of Chronic
Aortic Insufficiency Although vasodilator drugs acutely reduce regurgitation and improve cardiac performance in aortic insufficiency, their long-term effects on left ventricular size and function are uncertain. Consequently, we performed a double-blinded, placebo-controlled trial using hydralazine in 80 minimally symptomatic patients who had clinically stable, moderate-to-severe aortic insufficiency. Patients randomized to hydralazine displayed a progressive reduction in left ventricular end-diastolic volume index (LVEDVI) measured by radionuclide angiography, the predetermined end point of the study. At 24 months, mean LVEDVI had been reduced by 30 38 ml/m2, an 18% reduction from baseline. In contrast, LVEDVI changed minimally in patients randomized to placebo, and the intergroup differences over time were statistically significant (p<0.03). The hydralazine group also experienced reductions in left ventricular end-systolic volume index and increases in ejection fraction that were significantly different (both p<0.01) from changes in placebo-treated patients. These findings show that long-term treatment with hydralazine reduces the volume overload in aortic insufficiency and suggest that such therapy may have a beneficial effect on the natural history of the disease. (Circulation 1988;78:92-103) P revious studies have shown that vasodilator drugs acutely reduce the regurgitant volume and improve cardiac performance in aortic insufficiency. [1] [2] [3] [4] [5] [6] [7] Consequently, vasodilator therapy has emerged as an important modality for the shortterm management of patients with this lesion. These findings also raise the possibility that long-term therapy may chronically reduce the volume overload to the left ventricle.
The clinical course of chronic aortic insufficiency is characterized by a prolonged stable phase8-10 during which the left ventricle adapts to the regurgitant flow by alterations in size and function that From the Division of Cardiology, Department of Medicine, maintain cardiac performance in or close to the normal range." However, prolonged volume overload often leads to deterioration in left ventricular performance so that later in the course, signs and symptoms of cardiac dysfunction frequently develop.8,'0 An intriguing prospect is that the prophylactic administration of a vasodilator drug during the stable plateau phase of volume overload might be able to reduce either the extent of left ventricular dilation or its progression.
The present study was undertaken to test the hypothesis that long-term vasodilator therapy with oral hydralazine reduces the volume overload and, hence, the left ventricular end-diastolic volume in clinically stable, moderate-to-severe aortic insufficiency. It was conducted as a prospective, randomized, placebocontrolled, double-blinded trial with change in left ventricular volume measured by radionuclide angiography as the predetermined end point.
Patients and Methods Entry Criteria
Patients were recruited at the Oregon Health Sciences University, Portland, and at the University of California, San Francisco. The study proto- tAortic insufficiency developed as the result of a surgical procedure designed to relieve aortic stenosis. col had been approved by the institutional review board at these centers, and all patients gave informed consent before their participation in the trial. Entry criteria included evidence of significant aortic insufficiency by physical examination (defined as the presence of a characteristic aortic diastolic murmur and a pulse pressure -60 mm Hg by sphygmomanometry) and a left ventricular end-diastolic volume index (LVEDVI) -100 ml/m2 by radionuclide angiography. This value is the mean + 1.5 SD for normal subjects in our laboratories. Only patients who were asymptomatic or who had minimal nonlimiting symptoms were included in this trial. As shown in Table 1 , the distribution of patients who were considered to be New York Heart Association Functional Class I or early Class II was not signif-icantly different between the treatment groups. Patients with more severe symptoms were not enrolled in this clinical trial because they are usually referred for aortic valve replacement at our institutions. Patients were also excluded from the trial if any of the following were present: atrial fibrillation, uncontrolled hypertension (e.g., diastolic blood pressure .90 mm Hg by sphygmomanometry), previous aortic valve replacement, evidence that the aortic insufficiency had either developed or worsened within the preceding 12 months, or evidence that the aortic insufficiency was caused by aortic root dissection. Additional reasons for exclusion were evidence of coronary artery disease either by history, by the presence of a Q-wave infarction on electrocardiogram (ECG), or by angiography or of pregnancy (or failure to take precautions to avoid pregnancy). Patients with evidence of additional valvular or congenital lesions by physical examination or by noninvasive evaluation were excluded unless significant disease was ruled out by cardiac catheterization and angiography. Patients with a gradient of -25 mm Hg across the aortic valve, those with a mitral valve area <2.0 cm2, or those with more than trivial mitral regurgitation were excluded from the study.
Patient Evaluation and Randomization
The initial baseline evaluation of all patients included a complete history and physical examination performed by an experienced senior clinician, complete blood count, blood chemistry screen and urinalysis, 12-lead ECG, chest roentgenogram in the posteroanterior and lateral projections, radionuclear angiography for calculation of left ventricular volumes and ejection fraction (EF), and M-mode echocardiogram. The characteristics of the 80 patients who were enrolled and randomized in the trial are given in Table 1 . Cardiac catheterization that confirmed both the presence of at least moderately severe aortic insufficiency and the absence of other significant disease had been performed in 28 (35%) of the 80 patients. Coronary angiography had been performed in 18 of the 43 (42%) patients who were 40 or more years old.
Because it was anticipated that the dropout rate would be greater in patients randomized to active vasodilator medication, treatment assignments were weighted 55%:45% in favor of this group to ensure that approximately equal numbers of patients from the two groups would be taking the study drug on a long-term basis. Randomization was stratified according to both recruitment site (e.g., Portland or San Francisco) and whether the baseline radionuclide EF was >-0.50 or <0.50. The latter variable was used because it was believed that patients with an abnormally low EF were likely to progress at a different rate than patients with a normal EF. However, because only two patients with an EF <0.50 were enrolled (one in each group), separate analyses of these patients were not performed.
On completion of baseline studies, qualifying patients were begun on either hydralazine (25 mg p.o. b.i.d.) or a matching placebo tablet. Neither the study physicians nor the patients were aware of which treatment was given. The dosage of study medication was titrated up to a total of 3 mg/kg body wt daily in divided doses (usually b.i.d.) over a 2-4-week period. This dose was chosen based on our previous experience, which demonstrated that it would significantly improve cardiac function in patients with chronic aortic insufficiency412 and, in addition, would be less likely to cause unacceptable side elfects in a minimally symptomatic study population. Patients developing side effects attributable to the study drug had the dosage adjusted during the first 3 months of the study as necessary. At 3 months after randomization, the average dosage of hydralazine was 216 + 64 mg/day (mean SD) (range, 150-300 mg). Compliance, as assessed by pill count at each follow-up visit, averaged 86% for the entire study period and was similar for patients in the two groups. Repeat clinical, radionuclide angiographic, and echocardiographic evaluations were performed at 3, 6, 12, and 24 months after randomization.
Patients were withdrawn from treatment if they experienced any of the following: new or increasing symptoms referable to aortic insufficiency, intolerable side effects attributable to the study drug, a fall in resting EF below 0.50, the development of a medical condition that necessitated discontinuation of the study drug, or replacement of the aortic valve. Patients who no longer wished to participate and those who took <50% of the prescribed dose or less than a 100 mg total daily dosage of the study drug were also terminated from the trial. However, follow-up evaluation was performed in all randomized patients whenever possible for up to 24 months.
Radionuclide Angiography
In both centers, radionuclide angiography was performed with single crystal scintillation cameras interfaced with Medical Data Systems A2 computer systems (Ann Arbor, Michigan). The techniques of acquisition and analysis were identical at the two centers. The blood pool was labeled with 740-925 Mdps technetium-99m sodium pertechnetate by the in vivo red blood cell technique.' 3 Equilibrium blood pool scintigrams were collected in the anterior projection and in the left anterior oblique projection, which resulted in the optimal separation of left and right ventricles and ventricles from atria. The cardiac cycle was divided into 28 frames with a minimum of 300,000 counts/frame. A 5-mI blood sample was drawn from an indwelling venous catheter at the midpoint of the left anterior oblique scintigram. The equipment used, technologist performing the study, and position of the camera for 
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imaging were recorded at the time of the initial visit and kept constant during subsequent studies. The analysis technique used has been published previously. [14] [15] [16] Left ventricular regions of interest were generated by a semiautomatic, combinationthreshold, second-derivative edge detection algorithm applied to temporally and spatially smoothed data. These were manually adjusted when necessary. A time-activity curve was then generated from the unprocessed scintigrams after subtraction of a paraventricular background value. The left ventricular EF was calculated by standard techniques. Ventricular volumes were calculated from the radionuclide activity normalized for the radionuclide activity per milliliter of blood corrected for the acquisition time per frame and decay of radioisotope. No attenuation correction was attempted because the primary goal of the nuclear volume determinations was to assess changes in each individual patient over time. Thus, although the absolute volume measurements by this technique may have been alTected in some patients by differences in soft tissue attenuation, the measurement of relative changes would be less susceptible to variability. End-diastolic and end-systolic counts were then converted to absolute volumes according to regression equations relating the nuclear measurements to contrast ventriculograms generated in each laboratory.' 516 In Portland, the correlation coefficient between corrected left ventricular nuclear count ratios and ventricular volumes determined by contrast angiography was 0.99 with SEE of 13 ml; in San Francisco, the correlation coefficient was 0.98 with an SEE of 18 ml. A left ventricular-to-right ventricular stroke count ratio (SCR), a semiquantitative measure of regurgitant fraction, was determined by the techniques of Bough et al. 17 This measurement is consistently below 1.5 in our laboratories in patients who are without left heart valvular regurgitation, whereas patients with values -2.0 generally have moderate or severe regurgitation.
To further examine the compatibility of data obtained from the two laboratories, unprocessed studies performed in Portland were analyzed in San Francisco.'8 Results from this analysis showed an excellent correlation for left ventricular EF (r = 0.96, SEE = 2.99%), LVEDVI (r = 0.97, SEE = 7.2%), and left ventricular end-systolic volume index (LVESVI) (r= 0.98, SEE =9.6%) at the two institutions. Echocardiograms M-mode echocardiograms were obtained by standard techniques for data acquisition at each institution. '9 Studies were performed with dedicated M-mode echocardiographs in 30% of patients and M-mode tracings derived from two-dimensional machines in the remainder. The equipment used, the technologist performing the study, and the patient's position and echocardiographic window at the initial study were recorded and kept constant. Measurements were performed at the end of the trial on strips including 3-5 beats selected to reflect as close as possible the same level of the left ventricle and the same technique on the serial studies of each patient. These were then coded and read by two independent observers blinded to the patient's identity, treatment, and order of the studies. When the two readings resulted in discrepancies -3 mm for left ventricular end-diastolic dimension (LVEDD) or left ventricular end-systolic dimension (LVESD), the studies were read by a third observer, and agreement was achieved by consensus. Only studies that allowed unambiguous definition of the endocardial borders were included in the analysis. Overall, 26% of studies were excluded because of technical reasons or inadequate visualization.
Statistical Methods
The trial was designed to detect a 10% difference in the mean 1-year change in LVEDVI by radionuclide angiography between the two treatment groups. The probability of not detecting this 10% difference was specified as B= 0.1 for a one-tailed t test with significance level a = 0.05. The interstudy variability in LVEDVI in clinically stable patients with aortic insufficiency was determined in our laboratories to be 13% of the baseline mean.20 The calculated sample sizes were then increased to compen- 20 sate for anticipated dropout rates. Interim analysis of end point data was not performed. The effects of treatment on LVEDVI and other end points were not assessed until 1 year after a requisite number of patients had been randomized. The t test and x2 analysis were used for baseline comparisons ofthe treatment groups for several numerical and categorical characteristics, respectively.
Because of the spread of entry times, dropouts, and noncompliance, the duration of follow-up was variable. To remove potential biases that might occur with selective dropout or noncompliance in one of the treatment groups, intention-to-treat analyses were performed with data from all patients who were available for at least a single follow-up study regardless of whether they were taking the study drug. To remove bias that might result in comparing treatments with unequal distributions of follow-up, only the latest follow-up measurements were used in the intention-to-treat analyses. The changes in EDVI, ESVI, and EF from baseline to latest follow-up study were then compared in the two treatment groups by means of the t test. A one-tailed t test was used because the study was designed to test the unidirectional null hypothesis that the effects of hydralazine on left ventricular volumes and EF were no greater than those of the placebo.21
Subsequent analyses included only measurements obtained from patients who were still taking the study drug. Changes over time were determined by comparing a patient's measurements at each follow-up interval with that same individual's baseline measurements. A least-significant difference test approach was taken for simultaneous comparison of the mean change in variables obtained at visits at 3, 6, 12, and 24 months for the two treatment groups.22 This two-stage multiple comparison approach permits unequal size treatment groups and missing visits. In the first stage, a 5%-level F test is made for the null hypothesis that the mean changes at 3, 6, 12, and 24 months are identical for both groups. The usual split-plot analysis of variance (ANOVA) for a repeated measures design was used. 23 The null hypothesis of identical mean changes for the two treatments corresponds to the null hypothesis of zero TREATMENT by VISIT (e.g., 0, 3, 6, 12, and 24 months) interaction effects in the split-plot model. When the null hypothesis was rejected (e.g., the ANOVA value for the overall difference between treatment groups over time was <0.05), a second stage of analysis was pursued to determine when the groups differed. In this stage, the usual two-sample t test was used to compare mean changes at each individual visit (3. 6. 12, and 24 months) for the treatment groups.
Results

Baseline Comparisons
As shown in Table 1 , the clinical characteristics and descriptors of left ventricular size and function from the baseline noninvasive tests in the two groups of randomized patients were similar. Left ventricular enlargement, as evidenced by LVEDVI and LVEDD measurements, was considerable. The left ventricular-to-right ventricular SCR, which is a semiquantitative measure of regurgitation, was also markedly increased, supporting the presence of significant aortic insufficiency. The left ventricular EF was >0.50 in all but two patients.
Patient Follow-up
The follow-up of the 80 randomized patients is outlined in Table 2 . Four of the patients who had been randomized to the placebo and six who had been randomized to hydralazine were unavailable for follow-up evaluation. Of these 10 patients, nine Figure 1 . Patients receiving placebo (P) experienced a slight reduction in EF, whereas those receiving hydralazine showed an increase. Difference between the groups was highly significant. were clinically stable at 24 months, and one patient, who dropped out of the study due to an unplanned pregnancy, subsequently underwent valve replacement 3 years after randomization. The clinical characteristics and descriptors of left ventricular size and function for this group of 10 patients were not significantly different from those of the 70 randomized patients who were available for at least one follow-up radionuclide angiographic evaluation. These 70 randomized patients were included in the intention-to-treat analyses. Sixty-four of these patients (91%) were considered to be compliant and were taking at least 150 mg of medication daily at the time of the first follow-up visit. These patients were included in the received-treatment analyses. Subsequently, four patients who had been randomized to each treatment group discontinued the study drug between the 3-and 12-month follow-up evaluations. Of the patients who were available for follow-up, 77% of those assigned to hydralazine and 84% of those assigned to placebo were considered to be compliant at 12 months. An additional eight placebo-treated and four hydralazine-treated patients discontinued the study drug between 12 and 24 months into the trial. Overall, 13 of the 31 (42%) placebo patients who were available for follow-up evaluation stopped taking the study drug during the trial period. The reasons were noncompliance (n = 5), side effects (n = 2), progression to valve replacement (n = 2), noncardiac death (n = 1), and miscellaneous (n = 3).
Thirteen of the 39 (33%) patients randomized to hydralazine who were available for follow-up discontinued the study drug because of side effects (n = 7), noncompliance (n = 5), and miscellaneous (n= 1) causes.
Intention-to-Treat Analysis
To avoid bias that might be introduced by selective patient dropout from either treatment groups, the initial evaluation of radionuclear data was performed on all patients available for followup, regardless of whether they were taking the study drug. As shown in Table 2 , there were 70 patients available for this analysis. Bias due to inclusion of multiple data points from patients who were followed over a longer period of time was avoided by using only the latest set of measurements from each patient. These measurements were then compared with baseline measurements in the same patient. For EDVI, the predetermined primary end point of the study, there was a 24 + 6 ml/m2 reduction in the 39 patients randomized to hydralazine as opposed to a 5 + 7 ml/m2 reduction in the 31 patients who were given the placebo (p = 0.024). For ESVI, the hydralazine group experienced a 12+3 ml/m2 reduction as opposed to a 2 + 4 ml/ml increase in the placebo group (p = 0.005). Patients receiving the placebo decreased EF by 0.02 + 0.01 (p<0.OOl).
Received-Treatment Analysis
Because important differences were observed by the very conservative analysis described above, subsequent analyses were carried out by conventional ANOVA methods that assess changes over time. Applied to the received-treatment patients, these analyses indicate the physiological effects of drug therapy. The results of ANOVA analysis for key nuclear variables are depicted in Figures 1-4 . LVEDVI (Figure 1 ) did not change significantly in the placebo group. LVEDVI was reduced in a stepwise fashion in patients randomized to hydralazine, and for the 24-month period, these changes were highly significant compared with both baseline (p<0.OOl) and the changes seen in the placebo group (p = 0.022). LVEDVI was reduced by 30 + 38 ml/m2 (or 18% from the baseline value) in the 21 patients who were maintained on hydralazine for 24 months. Increases in LVEDVI of .25 ml/m2 above the baseline level were seen in two patients in the placebo group and in no patients in the hydralazine group.
Although there was a 5 + 7 ml/m2 (9%) increase in LVESVI at 24 months in the placebo group, the changes over time were not significantly different from baseline (Figure 2 ). In contrast, patients randomized to hydralazine exhibited a stepwise reduction in LVESVI over the 24-month study period. The reduction averaged 12 + 20 m1/m2 (2 1%) at 12 months and 16 + 24 ml/m2 (28%) at 24 months, and the overall changes over time were highly significant compared with both pretreatment values (p<0.001) and changes in the placebo group (p<0.003).
Placebo-treated patients displayed a small but statistically significant reduction in EF (Figure 3 ) over time (p<0.001). Hydralazine-treated patients exhibited an increase in EF (p<0.005), and the differences between the groups as assessed by ANOVA were highly significant. The SCR did not change in the placebo group (Figure 4 ), while it was significantly reduced in the hydralazine group, compared with both baseline (p<0.001) and the placebo group (p<0.009). Table 3 lists the mean values for heart rate, blood pressure, and echocardiographic variables for each group over time. No important differences or trends in any of these variables were noted.
Vital Signs and Echocardiographic Findings
Progression to Surgery
Although progression to aortic valve replacement was uncommon in this cohort of patients, three patients from the placebo group (10%) and one patient from the hydralazine group (2%) required surgery during the study period. The patient from the hydralazine group had discontinued study medication after 3 months becausv.-of side effects and subsequently had his aortic valve replaced 12 months after randomization. All four of the patients who required surgery had developed the new onset of limiting symptoms that were accompanied by evidence of left ventricular dysfunction in one patient and by a substantial increase in LVEDVI in another.
Side Effects
As shown in Table 4 , side effects were common in both placeboand hydralazine-treated patients. Between randomization and the 3-month follow-up visit, 44% of the patients randomized to the placebo and 76% of those randomized to hydralazine (p<0.001) complained of at least one new symptom. However, at the 12-month visit, side effects were present in only 8% of the placebo group and 13% of the hydralazine group (p = NS). During the course of the study, three of the 45 (7%) patients who were randomized to hydralazine developed a lupuslike syndrome. Symptoms resolved in all cases after the drug was discontinued. Discussion Although we have previously reported that hydralazine acutely improves cardiac performance in aortic insufficiency4,5 and that, at least in some cases, long-term therapy may be helpful, 12 a wellcontrolled, prospective trial was clearly necessary to determine whether long-term vasodilator therapy would be beneficial to patients with this disorder. The present study was designed to evaluate the effects of hydralazine in patients with at least moderate aortic insufficiency during the long stable 
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3 (8%) 1 (3%) 2 (5%) 6 (15%) 29 (76%)* *p<0.001 compared with placebo; tp = NS compared with placebo. phase of the disease. Left ventricular enlargement in the presence of the usual clinical findings associated with aortic insufficiency (e.g., characteristic diastolic murmur and wide pulse pressure) was required for entry into the trial. When clinical or noninvasive evaluation suggested the presence of another significant cardiac abnormality, enrollment was deferred until this possibility was excluded by cardiac catheterization and angiography. Patients who were randomized had at most mild, nonlimiting symptoms, and 78 of the 80 patients (98%) had a normal resting left ventricular EF. Thus, these patients were without current indications for surgery, but by virtue of their increased LVEDVI (which averaged 161 44 and 169 ±47 ml/m2 in the placebo and hydralazine groups, respectively) they were at risk for valve replacement in the future.
The question addressed in the present study was whether long-term hydralazine therapy could reduce the severity or progression of left ventricular dilatation in aortic insufficiency. Consequently, LVEDVI was chosen as the primary end point to be evaluated. Left ventricular dilatation develops in response to chronic regurgitant flow, and in general, it reflects the severity and duration of the valve lesion.1' Although in many cases the left ventricle can compensate for the chronic volume overload of aortic insufficiency for an extended period of time, systolic pump function often deteriorates when this condition is prolonged.8'10 Left ventricular size has been shown to be an important predictor of the requirement for future valve replacement.24.25 Thus, it is reasonable to speculate that a treatment producing sustained reductions in LVEDVI might also alter the natural history of the disease and delay the need for valve replacement. LVESVI, another important prognostic factor,24-29 and EF were also followed as end points in the trial.
The results of this double-blinded, placebocontrolled trial in patients with chronic aortic insufficiency and left ventricular enlargement clearly demonstrate that long-term hydralazine therapy favorably affects left ventricular size and function. The intention-to-treat analysis avoids potential biases due to selective patient dropout and varying length of follow-up by including all patients who were available for evaluation regardless of whether they were taking the study drug and by using only the latest set of measurements in each patient. Overall, this analysis demonstrated significant differences in response between treatment groups in EDVI, the primary end point of the trial, ESVI, and EF. The evaluation of patients who "received treatment," which assesses the physiological effects of therapy, demonstrated that both LVEDVI and LVESVI were progressively reduced in the group of patients treated with hydralazine and that over time changes were significantly different from those seen in patients randomized to the placebo. In patients who were maintained on the drug for 24 months, there was an 18% reduction in LVEDVI and a 28% reduction in LVESVI. Placebo The changes in left ventricular volumes that occurred in this trial appear to result from the effects of hydralazine on EF and regurgitant flow. Patients who received the active drug demonstrated small but statistically significant increases in EF and reductions in SCR. Although SCR has limited value in quantitating the severity of regurgitation and the response to therapy in individual patients due to large interstudy variability,30 measurement of this variable can be helpful in assessing changes in groups of patients. Because study-to-study variability should be random in patients with stable regurgitation, the mean value for SCR should not change significantly over time. This is what was seen in the present study in the group of patients who received the placebo. However, there were reductions in SCR over time in the hydralazine group, and compared with the placebo control group, these changes were highly significant. We have previously reported that hydralazine, a drug whose predominant effect is arterial dilation, will acutely increase EF and reduce the amount of regurgitation in patients with aortic insufficiency by lowering systemic vascular resistance.5 Although systemic vascular resistance could not be reliably measured by the methods used in this study, the changes that were seen in EF and SCR suggest that it was reduced and that this effect was maintained during long-term therapy. The absence of a significant reduction in blood pressure is not inconsistent with this possibility. In a previous study4 of patients with aortic insufficiency, hydralazine (in doses similar to those used in this study) reduced systemic vascular resistance by 36% without significantly altering heart rate or blood pressure. The explanation for this is that arterial pressure was maintained by a 59% increase in forward cardiac output. Enhanced emptying of the left ventricle because of a reduction in systemic vascular resistance could explain some of the changes in volume that were seen. However, any reduction in systemic vascular resistance should have been maximal by 2-4 weeks after initiation of therapy when the maintenance dose of hydralazine was reached and, thus, would not fully explain the progressive stepwise changes that were measured in EDVI and ESVI over 24 months. We have previously shown that the administration of hydralazine will acutely reduce left ventricular end-diastolic pressure in patients with aortic insufficiency.45 Pressure is a major determinant of ventricular wall stress. If hydralazine reduced end-diastolic pressure in the present trial, it is likely that diastolic wall stress would have also been reduced. Because increases in wall stress have been postulated to play a role in the development of left ventricular dilatation,3' a sustained reduction in diastolic wall stress may have been responsible for remodeling the left ventricle into a smaller chamber. Such slow remodeling with hydralazine therapy may be analogous to changes that occur in the late after-surgery period after valve replacement for aortic insufficiency. Immediately after surgery, left ventricular volumes decrease rapidly as a result of the termination of regurgitant flow. However, further regression of left ventricular dilatation often continues for several more months,32-34 presumably as a result of changes in loading conditions.
Overall, there was little evidence of progressive left ventricular dilatation or dysfunction in the placebo group. This is consistent with previous reports demonstrating that left ventricular volumes may remain constant for extended periods in patients with long-standing aortic insufficiency.2425 Although this trial was not designed to assess the impact of hydralazine on the progression to surgery, it is noteworthy that three patients from the placebo group and only one from the hydralazine group required aortic valve replacement. In addition, three patients who received a placebo but none who were randomized to hydralazine displayed a reduction in left ventricular EF of at least eight units to a level that was 0.55 or below. Reductions in EF of this magnitude exceed the interstudy variability in our laboratories.20 It is our experience that such changes often herald progression to the symptomatic state and are, in our practice, an indication for more frequent follow-up evaluation. In this study, we observed no significant differences in M-mode echocardiographic variables between the treatment groups over time. We have shown that the interstudy variability in echocardiographic measurements in stable aortic insufficiency patients with large ventricles is considerable, averaging 6.1% for end-diastolic and 10.1% for endsystolic dimension. 35 For this reason and because only 74% of the echocardiograms were considered to be of sufficient quality to perform accurate and reliable measurements, a far larger study population would have been required to demonstrate a reduction in left ventricular volumes by M-mode echocardiography. The discordance in findings between the techniques can also be explained by observations made in our laboratory and elsewhere that M-mode echocardiograms do not accurately measure left ventricular volumes in patients with aortic insufficiency. 36, 37 In addition, St. John Sutton et a138 have reported that the M-mode echocardiogram was insensitive to reductions in left ventricular volumes that occurred when nitroglycerin was administered to patients with aortic insufficiency.38 Because these conditions were anticipated when designing the trial, we predetermined that echocardiographic measurements were not to be considered as primary end points. Two-dimensional echocardiograms are superior in aortic insufficiency,3738 but, unfortunately, because of the timing of the study, these were not available at baseline in many of our patients. Nonetheless, when serial twodimensional echocardiograms were reviewed in a small group of patients, there was much better concordance of the nuclear results with these than with M-mode studies. Two patients are illustrative of the problem with the latter technique. These patients exhibited 36% and 40% reductions in LVEDVI between baseline and follow-up nuclear study. Their two-dimensional echocardiograms showed similar 27% and 45% decreases in LVEDVI, respectively, but the end-diastolic dimension on M-mode increased by 6 mm in the first patient and fell by only 1 mm in the second.
Because a proportion of the patients enrolled in this trial were taking digitalis or diuretics initially, treatment for the entire study population was not uniform. However, the distribution of patients receiving these drugs was similar between groups. It is our experience that practicing physicians often prescribe digitalis and/or diuretics for patients with moderate-to-severe aortic insufficiency, particularly when there is evidence of substantial cardiomegaly. Thus, inclusion of patients who were taking these drugs in the trial allowed us to study a population who would be at relatively greater risk of progressing to valve replacement in the future and in whom practicing clinicians would be more likely to consider starting a vasodilator to prevent or delay this possibility. Neither treatment with digitalis and/or diuretics nor the presence or absence of mild nonlimiting symptoms affected dropout rates in the trial.
Guidelines for the hydralazine dose used in the present study were based on our previous clinical experience that showed dosages of 50-150 mg given twice daily had beneficial effects on left ventricular performance in patients with aortic insufficiency4 and that higher doses were poorly tolerated in asymptomatic, active patients. In addition, doses in this range are often used to treat patients with hypertension. As discussed earlier, the absence of a reduction in arterial pressure should not be misconstrued as an indication that an inadequate dose of drug has been given because drug-induced increases in cardiac output can balance the fall in resistance and maintain arterial pressure. It is, however, possible that a larger dose of hydralazine would have resulted in an even greater reduction in left ventricular volumes than was seen in this study.
The only other reported study evaluating the long-term effects of hydralazine in aortic insufficiency is that by Kleaveland et al. 39 These investigators performed a double-blinded trial in which patients with chronic aortic insufficiency were randomized to either hydralazine or a placebo. Although systolic wall stress was reduced in the hydralazine group, there were no significant differences in cardiac size between the treatment groups. The disparity between our present study and the previous study probably reflects their small sample size (n = 6 in the hydralazine group), limited follow-up period of only 6 months, and use of M-mode echocardiography for evaluating patients. All of these factors would contribute to the likelihood of failing to detect important differences between study groups (e.g., type IL error).
Clinical Implications
These findings have potentially important clinical implications. As discussed previously, increased left ventricular end-diastolic volume reflects the severity of the disease and is a predictor of the subsequent need for surgery. 11, 24, 25 LVESVI, which was also decreased with hydralazine (by 28% at 2 years), is an even more powerful predictor of future deterioration in left ventricular performance. [24] [25] [26] [27] [28] This may be related to the fact that this variable is an important determinant of left ventricular wall stress,3' a factor that strongly influences left ventricular function in patients with aortic valve disease.28,29A40-42 Whether vasodilator-induced changes in these measurements influence the outcome of patients with chronic aortic insufficiency still must be determined in future studies. Although the need for surgery was not a primary end point because of the limited sample size, it is noteworthy that the number of patients who either required surgery or displayed clinically worrisome reductions in resting EF that might herald the need for valve replacement was substantially greater in the placebo than in the drug group (e.g., 6:35 vs. 1:45).
Although conclusive evidence that the necessity for aortic valve replacement can be delayed or prevented is lacking, our observations suggest that prophylactic vasodilator therapy has the potential to alter the natural history of chronic aortic insufficiency. A larger and longer trial would be required to ascertain that vasodilator therapy could delay surgery and which subsets are most likely to benefit. In the meantime, we feel that it is reasonable to treat patients at highest risk for future deterioration, namely those with cardiac dilation, with vasodilators.
Hydralazine was chosen for this trial because it is a relatively pure arteriolar dilator and was thus well suited to test our hypothesis that lowering peripheral resistance would reduce regurgitation and, hence, heart size. Since the initiation of our trial, angiotensin-converting enzyme inhibitors and calcium channel blockers have become available. These agents may also be effective, but this needs to be evaluated. Hydralazine therapy was well tolerated by most patients, but a sizable minority (including three who developed a lupuslike syndrome) had side effects. Nonetheless, based on the results of our study, we use hydralazine initially but change to other agents if it is not tolerated. 
